Hopital Prive Drome-Ardeche

Research site

France 294 Boulevard Charles De Gaulle, 07500 Guilherand-Granges, France

2 trials recruiting
Hormone receptor positive HER2 negative breast cancer · Gastrointestinal cancer metastatic · Hormone-refractory prostate cancer
Adult patients

About Specializations

Hopital Prive Drome-Ardeche in Guilherand-Granges, France specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Gastrointestinal cancer metastatic, Hormone-refractory prostate cancer, Squamous cell carcinoma of head and neck, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

294 Boulevard Charles De Gaulle07500 Guilherand-GrangesFrance

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 4

More sites in Guilherand-Granges France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

5 clinical trials

Gastrointestinal cancer metastatic

Recruiting

Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

Registered drugNo placebo

Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Unicancer

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Darolutamide
Sponsor:Unicancer

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Unicancer

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational

France

Participants:18–64 years · 65+ years
Substances:Xevinapant
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Registered drugNo placebo

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites